Search filters

List of works by Peter J. Houghton

A Phase I Study of Cixutumumab (IMC-A12) in Combination with Temsirolimus (CCI-779) in Children with Recurrent Solid Tumors: A Children's Oncology Group Phase I Consortium Report

scientific article

A Phase II Study of Alisertib in Children with Recurrent/Refractory Solid Tumors or Leukemia: Children's Oncology Group Phase I and Pilot Consortium (ADVL0921)

scientific article published on 18 February 2019

A Proposal Regarding Reporting of In Vitro Testing Results ⬇️

scientific article published on April 11, 2013

A novel small molecular STAT3 inhibitor, LY5, inhibits cell viability, cell migration, and angiogenesis in medulloblastoma cells

scientific article published on 13 October 2014

A phase I trial of MK-2206 in children with refractory malignancies: a Children's Oncology Group study

scientific article published on 24 March 2014

A pilot study of protracted topotecan dosing using a pharmacokinetically guided dosing approach in children with solid tumors

scientific article

A single-arm pilot phase II study of gefitinib and irinotecan in children with newly diagnosed high-risk neuroblastoma ⬇️

scientific article published on July 28, 2011

A very long-acting Poly(ADP-ribose) polymerase inhibitor suppresses cancer cell growth in DNA repair-deficient tumor models

scientific article published on 15 December 2020

AKR1C3 is a biomarker of sensitivity to PR-104 in preclinical models of T-cell acute lymphoblastic leukemia

scientific article

Abemaciclib Is Active in Preclinical Models of Ewing Sarcoma via Multipronged Regulation of Cell Cycle, DNA Methylation, and Interferon Pathway Signaling

scientific article published on 21 August 2018

Activation and antitumor activity of CPT-11 in plasma esterase-deficient mice

scientific article published on 26 May 2005

Acute Sensitivity of Ph-like Acute Lymphoblastic Leukemia to the SMAC-Mimetic Birinapant.

scientific article published on 14 June 2016

Age-associated genes in human mammary gland drive human breast cancer progression

scientific article published on 15 June 2020

Altered irinotecan pharmacokinetics in pediatric high-grade glioma patients receiving enzyme-inducing anticonvulsant therapy

scientific article

Anti-Angiogenic Activity of a Small Molecule STAT3 Inhibitor LLL12 ⬇️

scientific article published on April 17, 2012

Assessing cytotoxic treatment effects in preclinical tumor xenograft models

scientific article

Biology of childhood osteogenic sarcoma and potential targets for therapeutic development: meeting summary.

scientific article published on November 2003

Bioluminescence Imaging Enhances Analysis of Drug Responses in a Patient-Derived Xenograft Model of Pediatric ALL.

scientific article published on 24 January 2017

Broad Spectrum Activity of the Checkpoint Kinase 1 Inhibitor Prexasertib as a Single Agent or Chemopotentiator Across a Range of Preclinical Pediatric Tumor Models

scientific article published on 18 December 2018

Canine osteosarcoma genome sequencing identifies recurrent mutations in DMD and the histone methyltransferase gene SETD2

scientific article published on 19 July 2019

Cefixime allows greater dose escalation of oral irinotecan: a phase I study in pediatric patients with refractory solid tumors

scientific article published in February 2006

Cell and molecular determinants of in vivo efficacy of the BH3 mimetic ABT-263 against pediatric acute lymphoblastic leukemia xenografts

scientific article

Classical NF-κB Metabolically Reprograms Sarcoma Cells Through Regulation of Hexokinase 2.

scientific article published on 11 April 2018

Combination testing (Stage 2) of the Anti-IGF-1 receptor antibody IMC-A12 with rapamycin by the pediatric preclinical testing program.

scientific article

Combination testing of cediranib (AZD2171) against childhood cancer models by the pediatric preclinical testing program.

scientific article published on 29 April 2011

Combining targeted agents with modern radiotherapy in soft tissue sarcomas

scientific article

Credentialing preclinical pediatric xenograft models using gene expression and tissue microarray analysis

scientific article published on January 2007

Development and characterization of the novel human osteosarcoma cell line COS-33 with sustained activation of the mTOR pathway

scientific article published on 07 July 2020

Development, characterization, and reversal of acquired resistance to the MEK1 inhibitor selumetinib (AZD6244) in an in vivo model of childhood astrocytoma

scientific article

Differential regulation of vascular endothelial growth factor by Akt and mammalian target of rapamycin inhibitors in cell lines derived from childhood solid tumors

scientific article published on 4 May 2007

Dose escalation of intravenous irinotecan using oral cefpodoxime: A phase I study in pediatric patients with refractory solid tumors ⬇️

scientific article published on April 20, 2011

Dose-response effect of eribulin in preclinical models of osteosarcoma by the pediatric preclinical testing consortium

scientific article published on 24 July 2020

Dual Targeting of the Type 1 Insulin-like Growth Factor Receptor and Its Ligands as an Effective Antiangiogenic Strategy ⬇️

scientific article published on April 2, 2013

ET-59DEVELOPMENT AND CHARACTERIZATION OF A MEK1 INHIBITOR (AZD6244) SENSITIVE CHILDHOOD ASTROCYTOMA CELL LINE

scientific article published in November 2014

Effective targeting of the P53-MDM2 axis in preclinical models of infant MLL-rearranged acute lymphoblastic leukemia

scientific article

Efficacy and pharmacokinetic/pharmacodynamic evaluation of the Aurora kinase A inhibitor MLN8237 against preclinical models of pediatric cancer.

scientific article published on 30 March 2011

Efficacy and toxicity of a virus-directed enzyme prodrug therapy purging method: preclinical assessment and application to bone marrow samples from neuroblastoma patients

scientific article

Efficacy of CPX-351, (cytarabine:daunorubicin) liposome injection, against acute lymphoblastic leukemia (ALL) xenograft models of the Pediatric Preclinical Testing Program

scientific article

Emerging novel agents for patients with advanced Ewing sarcoma: a report from the Children's Oncology Group (COG) New Agents for Ewing Sarcoma Task Force

scientific article published on 15 April 2019

Enhanced antitumor activity of irofulven in combination with irinotecan in pediatric solid tumor xenograft models

scientific article published on 16 October 2004

Establishment of human tumor xenografts in immunodeficient mice

scientific article

Evaluation of ABT-751 against childhood cancer models in vivo

scientific article published on 24 March 2007

Evaluation of Alternative In Vivo Drug Screening Methodology: A Single Mouse Analysis

scientific article published on 5 August 2016

Evaluation of Eribulin Combined with Irinotecan for Treatment of Pediatric Cancer Xenografts

scientific article published on 17 March 2020

Evaluation of VTP-50469, a menin-MLL1 inhibitor, against Ewing sarcoma xenograft models by the pediatric preclinical testing consortium

scientific article published on 25 April 2020

Evaluation of arsenic trioxide by the pediatric preclinical testing program with a focus on Ewing sarcoma.

scientific article published on 7 February 2012

Evaluation of cytarabine against Ewing sarcoma xenografts by the pediatric preclinical testing program ⬇️

scientific article published on December 1, 2010

Evaluation of entinostat alone and in combination with standard-of-care cytotoxic agents against rhabdomyosarcoma xenograft models

scientific article published on 16 May 2019

Evaluation of patritumab with or without erlotinib in combination with standard cytotoxic agents against pediatric sarcoma xenograft models.

scientific article published on 28 October 2017

Evaluation of the antitumor efficacy, pharmacokinetics, and pharmacodynamics of the histone deacetylase inhibitor depsipeptide in childhood cancer models in vivo

scientific article published on January 2006

Evaluation of the in vitro and in vivo efficacy of the JAK inhibitor AZD1480 against JAK-mutated acute lymphoblastic leukemia

scientific article

Forty-five patient-derived xenografts capture the clinical and biological heterogeneity of Wilms tumor

scientific article published on 20 December 2019

GDF6-CD99 Signaling Regulates Src and Ewing Sarcoma Growth

scientific article published on 01 November 2020

Gefitinib enhances the antitumor activity and oral bioavailability of irinotecan in mice

scientific article

Gefitinib modulates the function of multiple ATP-binding cassette transporters in vivo

scientific article published on May 2006

Genomic Profiling of Childhood Tumor Patient-Derived Xenograft Models to Enable Rational Clinical Trial Design

scientific article published on 01 November 2019

HG-06INHIBITION OF EPIGENETIC REGULATION AS A THERAPY FOR PEDIATRIC HIGH GRADE GLIOMA.

scientific article published on 21 April 2015

Identification of N10-substituted phenoxazines as potent and specific inhibitors of Akt signaling

scientific article published on 11 July 2005

Identifying novel therapeutic agents using xenograft models of pediatric cancer

scientific article published on 18 May 2016

Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro

scientific article published on April 2004

Improved response in high-risk neuroblastoma with protracted topotecan administration using a pharmacokinetically guided dosing approach

scientific article published in June 2005

In vivo evaluation of ixabepilone (BMS247550), a novel epothilone B derivative, against pediatric cancer models

scientific article published on October 2005

In vivo evaluation of the EZH2 inhibitor (EPZ011989) alone or in combination with standard of care cytotoxic agents against pediatric malignant rhabdoid tumor preclinical models-A report from the Pediatric Preclinical Testing Consortium

scientific article published on 22 October 2020

Inhibition of MDM2 by RG7388 confers hypersensitivity to X-radiation in xenograft models of childhood sarcoma

scientific article

Inhibition of MEK confers hypersensitivity to X-radiation in the context of BRAF mutation in a model of childhood astrocytoma

scientific article

Initial Testing (Stage 1) of MK-8242-A Novel MDM2 Inhibitor-by the Pediatric Preclinical Testing Program.

scientific article published on 30 May 2016

Initial Testing of NSC 750854, a Novel Purine Analog, Against Pediatric Tumor Models by the Pediatric Preclinical Testing Program

scientific article

Initial in vivo testing of a multitarget kinase inhibitor, regorafenib, by the Pediatric Preclinical Testing Consortium

scientific article published on 24 March 2020

Initial solid tumor testing (stage 1) of AZD1480, an inhibitor of Janus kinases 1 and 2 by the pediatric preclinical testing program

scientific article

Initial testing (Stage 1) of AT13387, an HSP90 inhibitor, by the pediatric preclinical testing program.

scientific article

Initial testing (Stage 1) of TAK-701, a humanized hepatocyte growth factor binding antibody, by the Pediatric Preclinical Testing Program.

scientific article published on 09 September 2013

Initial testing (Stage 1) of the antibody-maytansinoid conjugate, IMGN901 (Lorvotuzumab mertansine), by the pediatric preclinical testing program

scientific article

Initial testing (stage 1) by the pediatric preclinical testing program of RO4929097, a γ-secretase inhibitor targeting notch signaling

scientific article published on 16 August 2011

Initial testing (stage 1) of AZD6244 (ARRY-142886) by the Pediatric Preclinical Testing Program.

scientific article

Initial testing (stage 1) of BAL101553, a novel tubulin binding agent, by the pediatric preclinical testing program

scientific article published on 18 November 2014

Initial testing (stage 1) of LCL161, a SMAC mimetic, by the Pediatric Preclinical Testing Program

scientific article published on 16 June 2011

Initial testing (stage 1) of M6620 (formerly VX-970), a novel ATR inhibitor, alone and combined with cisplatin and melphalan, by the Pediatric Preclinical Testing Program.

scientific article published on 17 September 2017

Initial testing (stage 1) of SGI-1776, a PIM1 kinase inhibitor, by the pediatric preclinical testing program.

scientific article published on 2 November 2011

Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program

scientific article published on June 2008

Initial testing (stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing program

scientific article

Initial testing (stage 1) of ganetespib, an Hsp90 inhibitor, by the Pediatric Preclinical Testing Program

scientific article

Initial testing (stage 1) of glembatumumab vedotin (CDX-011) by the pediatric preclinical testing program.

scientific article

Initial testing (stage 1) of lapatinib by the pediatric preclinical testing program

scientific article published on October 2009

Initial testing (stage 1) of mapatumumab (HGS-ETR1) by the pediatric preclinical testing program

scientific article published on February 2010

Initial testing (stage 1) of sunitinib by the pediatric preclinical testing program

scientific article

Initial testing (stage 1) of tazemetostat (EPZ-6438), a novel EZH2 inhibitor, by the Pediatric Preclinical Testing Program

scientific article published on 24 August 2016

Initial testing (stage 1) of temozolomide by the pediatric preclinical testing program

scientific article

Initial testing (stage 1) of the Akt inhibitor GSK690693 by the pediatric preclinical testing program.

scientific article

Initial testing (stage 1) of the BH3 mimetic ABT-263 by the pediatric preclinical testing program

scientific article published on June 2008

Initial testing (stage 1) of the IGF-1 receptor inhibitor BMS-754807 by the pediatric preclinical testing program.

scientific article

Initial testing (stage 1) of the PARP inhibitor BMN 673 by the pediatric preclinical testing program: PALB2 mutation predicts exceptional in vivo response to BMN 673.

scientific article published on 27 September 2014

Initial testing (stage 1) of the Polo-like kinase inhibitor volasertib (BI 6727), by the Pediatric Preclinical Testing Program.

scientific article

Initial testing (stage 1) of the anti-microtubule agents cabazitaxel and docetaxel, by the pediatric preclinical testing program.

scientific article published on 7 July 2015

Initial testing (stage 1) of the curaxin CBL0137 by the pediatric preclinical testing program.

scientific article published on 21 September 2016

Initial testing (stage 1) of the cyclin dependent kinase inhibitor SCH 727965 (dinaciclib) by the pediatric preclinical testing program.

scientific article

Initial testing (stage 1) of the histone deacetylase inhibitor, quisinostat (JNJ-26481585), by the Pediatric Preclinical Testing Program

scientific article

Initial testing (stage 1) of the investigational mTOR kinase inhibitor MLN0128 by the pediatric preclinical testing program

scientific article

Initial testing (stage 1) of the kinesin spindle protein inhibitor ispinesib by the pediatric preclinical testing program.

scientific article published on December 2009

Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program.

scientific article

Initial testing (stage 1) of the mTOR kinase inhibitor AZD8055 by the pediatric preclinical testing program

scientific article

Initial testing (stage 1) of the multi-targeted kinase inhibitor sorafenib by the pediatric preclinical testing program

scientific article published on December 2010

Initial testing (stage 1) of the notch inhibitor PF-03084014, by the pediatric preclinical testing program

scientific article

Initial testing (stage 1) of the phosphatidylinositol 3' kinase inhibitor, SAR245408 (XL147) by the pediatric preclinical testing program.

scientific article

Initial testing (stage 1) of the polyamine analog PG11047 by the pediatric preclinical testing program.

scientific article

Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program.

scientific article published on January 2008

Initial testing (stage 1) of the topoisomerase II inhibitor pixantrone, by the pediatric preclinical testing program.

scientific article published on 26 October 2013

Initial testing (stage 1) of the tubulin binding agent nanoparticle albumin-bound (nab) paclitaxel (Abraxane(®)) by the Pediatric Preclinical Testing Program (PPTP).

scientific article

Initial testing (stage 1) of vorinostat (SAHA) by the pediatric preclinical testing program.

scientific article published on September 2009

Initial testing of JNJ-26854165 (Serdemetan) by the pediatric preclinical testing program.

scientific article published on 15 September 2011

Initial testing of VNP40101M (Cloretazine) by the pediatric preclinical testing program

scientific article

Initial testing of VS-4718, a novel inhibitor of focal adhesion kinase (FAK), against pediatric tumor models by the Pediatric Preclinical Testing Program.

scientific article published on 27 October 2016

Initial testing of a monoclonal antibody (IMC-A12) against IGF-1R by the Pediatric Preclinical Testing Program.

scientific article

Initial testing of aplidin by the pediatric pre-clinical testing program.

scientific article published on September 2009

Initial testing of cisplatin by the pediatric preclinical testing program

scientific article published on May 2008

Initial testing of dasatinib by the pediatric preclinical testing program

scientific article

Initial testing of lenalidomide by the pediatric preclinical testing program

scientific article published on 25 February 2011

Initial testing of the CENP-E inhibitor GSK923295A by the pediatric preclinical testing program

scientific article

Initial testing of the MDM2 inhibitor RG7112 by the Pediatric Preclinical Testing Program

scientific article

Initial testing of the VEGFR inhibitor AZD2171 by the pediatric preclinical testing program

scientific article published on March 2008

Initial testing of the aurora kinase A inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP).

scientific article

Initial testing of the hypoxia-activated prodrug PR-104 by the pediatric preclinical testing program.

scientific article

Initial testing of the investigational NEDD8-activating enzyme inhibitor MLN4924 by the pediatric preclinical testing program.

scientific article published on 19 October 2011

Initial testing of the multitargeted kinase inhibitor pazopanib by the pediatric preclinical testing program ⬇️

scientific article published on December 20, 2011

Initial testing of the replication competent Seneca Valley virus (NTX-010) by the pediatric preclinical testing program

scientific article

Initial testing of topotecan by the pediatric preclinical testing program.

scientific article

Insulin-like growth factor 1 receptor and response to anti-IGF1R antibody therapy in osteosarcoma

scientific article

Interval approach to assessing antitumor activity for tumor xenograft studies

scientific article

Intrinsic Resistance to Cixutumumab Is Conferred by Distinct Isoforms of the Insulin Receptor

scientific article published on 11 August 2015

MiR-584-5p potentiates vincristine and radiation response by inducing spindle defects and DNA damage in medulloblastoma

scientific article published in Nature Communications

Molecular characterization of the pediatric preclinical testing panel

scientific article

National Cancer Institute pediatric preclinical testing program: model description for in vitro cytotoxicity testing

scientific article

O6-benzylguanine-mediated enhancement of chemotherapy.

scientific article published in September 2002

PCAT: an integrated portal for genomic and preclinical testing data of pediatric cancer patient-derived xenograft models

scientific article published on 18 August 2020

PDX-MI: Minimal Information for Patient-Derived Tumor Xenograft Models.

scientific article published in November 2017

Pharmacodynamic and genomic markers associated with response to the XPO1/CRM1 inhibitor selinexor (KPT-330): A report from the pediatric preclinical testing program.

scientific article

Pharmacokinetic modeling optimizes inhibition of the 'undruggable' EWS-FLI1 transcription factor in Ewing Sarcoma

scientific article published on January 2014

Pharmacologic inhibition of cyclin-dependent kinase 4/6 activity arrests proliferation in myoblasts and rhabdomyosarcoma-derived cells

scientific article published on May 2006

Phase I and pharmacokinetic study of topotecan administered orally once daily for 5 days for 2 consecutive weeks to pediatric patients with refractory solid tumors

scientific article

Phase I study of depsipeptide in pediatric patients with refractory solid tumors: a Children's Oncology Group report

scientific article published on 01 August 2006

Phase I study of everolimus in pediatric patients with refractory solid tumors

scientific article published in October 2007

Phase I trial of temozolomide and protracted irinotecan in pediatric patients with refractory solid tumors

scientific article published on February 2004

Potent Inhibition of Angiogenesis by the IGF-1 Receptor-Targeting Antibody SCH717454 Is Reversed by IGF-2 ⬇️

scientific article published on December 21, 2011

Preclinical Characterization of OSI-027, a Potent and Selective Inhibitor of mTORC1 and mTORC2: Distinct from Rapamycin ⬇️

scientific article published on June 14, 2011

Preclinical Chemotherapeutic Tumor Models of Common Childhood Cancers: Solid Tumors, Acute Lymphoblastic Leukemia, and Disseminated Neuroblastoma ⬇️

scientific article published on 01 December 2007

Preclinical Childhood Sarcoma Models: Drug Efficacy Biomarker Identification and Validation

scientific article

Preclinical activity of the antibody-drug conjugate denintuzumab mafodotin (SGN-CD19A) against pediatric acute lymphoblastic leukemia xenografts

scientific article published on 23 April 2019

Preclinical evaluation of the combination of AZD1775 and irinotecan against selected pediatric solid tumors: A Pediatric Preclinical Testing Consortium report

scientific article published on 23 January 2020

Prospective use of the single-mouse experimental design for the evaluation of PLX038A

scientific article published on 11 January 2020

Quantitative phosphotyrosine profiling of patient-derived xenografts identifies therapeutic targets in pediatric leukemia.

scientific article published on 9 March 2016

R1507, a fully human monoclonal antibody targeting IGF-1R, is effective alone and in combination with rapamycin in inhibiting growth of osteosarcoma xenografts

scientific article

RAC1: an emerging therapeutic option for targeting cancer angiogenesis and metastasis

scientific article published on 26 September 2013

Radiation therapy may increase metastatic potential in alveolar rhabdomyosarcoma

scientific article published on 19 March 2015

Regulation of mammalian target of rapamycin complex 1 (mTORC1) by hypoxia: causes and consequences ⬇️

scientific article published on April 16, 2011

Relation between Irofulven (MGI-114) systemic exposure and tumor response in human solid tumor xenografts.

scientific article published in September 2002

Relationship of DNA methylation to mutational changes and transcriptional organization in fusion-positive and fusion-negative rhabdomyosarcoma

scientific article published on 15 January 2019

Results of a phase II upfront window of pharmacokinetically guided topotecan in high-risk medulloblastoma and supratentorial primitive neuroectodermal tumor

scientific article

SK-NEP-1 and Rh1 are Ewing family tumor lines

scientific article published on March 2008

Small molecules, LLL12 and FLLL32, inhibit STAT3 and exhibit potent growth suppressive activity in osteosarcoma cells and tumor growth in mice ⬇️

scientific article published on February 22, 2011

Stage 1 testing and pharmacodynamic evaluation of the HSP90 inhibitor alvespimycin (17-DMAG, KOS-1022) by the pediatric preclinical testing program.

scientific article published on July 2008

Stage 2 combination testing of rapamycin with cytotoxic agents by the Pediatric Preclinical Testing Program

scientific article

Synergism of FAK and tyrosine kinase inhibition in Ph+ B-ALL.

scientific article published on 7 April 2016

Synergistic activity of PARP inhibition by talazoparib (BMN 673) with temozolomide in pediatric cancer models in the pediatric preclinical testing program.

scientific article

Targeting Glycoprotein NMB With Antibody-Drug Conjugate, Glembatumumab Vedotin, for the Treatment of Osteosarcoma.

scientific article published on 25 August 2015

Temozolomide after radiotherapy for newly diagnosed high-grade glioma and unfavorable low-grade glioma in children

scientific article published in February 2006

Testing of new agents in childhood cancer preclinical models: meeting summary

scientific article published on 01 December 2002

Testing of the Akt/PKB inhibitor MK-2206 by the Pediatric Preclinical Testing Program.

scientific article published on 18 November 2011

Testing of the topoisomerase 1 inhibitor Genz-644282 by the pediatric preclinical testing program.

scientific article

The Bromodomain BET Inhibitor JQ1 Suppresses Tumor Angiogenesis in Models of Childhood Sarcoma

scientific article published on 23 February 2016

The anti-CD19 antibody-drug conjugate SAR3419 prevents hematolymphoid relapse postinduction therapy in preclinical models of pediatric acute lymphoblastic leukemia.

scientific article published on 20 February 2013

The application of radiation therapy to the pediatric preclinical testing program (PPTP): Results of a pilot study in rhabdomyosarcoma ⬇️

scientific article published on June 12, 2012

The emerging role of irinotecan (CPT-11) in the treatment of malignant glioma in brain tumors

scientific article

The importance of tumor glucuronidase in the activation of irinotecan in a mouse xenograft model.

scientific article published in November 2002

The insulin-like growth factor-1 receptor-targeting antibody, CP-751,871, suppresses tumor-derived VEGF and synergizes with rapamycin in models of childhood sarcoma

scientific article

The pediatric preclinical testing program: description of models and early testing results.

scientific article published in December 2007

Therapeutic targeting of ependymoma as informed by oncogenic enhancer profiling

scientific article published on 20 December 2017

Toward a drug development path that targets metastatic progression in osteosarcoma.

scientific article

Tumor secreted ANGPTL2 facilitates recruitment of neutrophils to the lung to promote lung pre-metastatic niche formation and targeting ANGPTL2 signaling affects metastatic disease

scientific article published on 04 February 2020

Two consecutive phase II window trials of irinotecan alone or in combination with vincristine for the treatment of metastatic rhabdomyosarcoma: the Children's Oncology Group

scientific article published on 01 February 2007

Tyrosine kinase inhibitor enhances the bioavailability of oral irinotecan in pediatric patients with refractory solid tumors

scientific article published on 17 August 2009

Venetoclax responses of pediatric ALL xenografts reveal sensitivity of MLL-rearranged leukemia.

scientific article

miR-29 acts as a decoy in sarcomas to protect the tumor suppressor A20 mRNA from degradation by HuR.

scientific article published on 30 July 2013

microRNA profiling identifies cancer-specific and prognostic signatures in pediatric malignancies.

scientific article published on 25 August 2009

p53/TAp63 and AKT regulate mammalian target of rapamycin complex 1 (mTORC1) signaling through two independent parallel pathways in the presence of DNA damage

scientific article published on 23 December 2013

Paulina is supported by:

About Paulina

Help